Clinical trials: Dysfunction, Left Ventricular
HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
Cardiac Safety Study in Patients With HER2 + Breast Cancer
HER2 positive breast cancer cells have more HER2 receptor (a protein on the surface of cells) than normal breast cells. Approximately 30% of patients with breast cancer have HER2 positive breast cancer.
- Trial name
- SAFE-HEaRt (NCT01904903)
- Testing
- Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Medstar Health Research Institute
Heart Failure, Congestive, Ventricular Dysfunction
Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation
The purpose of this study is to determine the safety and effectiveness of the Thoratec HeartMate II Left Ventricular Assist System (LVAS) as a bridge to cardiac transplantation in end-stage heart failure patients who are listed…
- Conditions
- Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
- Trial name
- NCT00121472
- Testing
- Thoratec HeartMate II Left Ventricular Assist System (LVAS)
- Where
- 36 sites in United States, Canada
- Volunteers
- 194 people
- Sponsor
- Abbott Medical Devices
Stem Cell Transplantation, Ventricular Dysfunction, Left
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional…
- Trial name
- TAC-HFT (NCT00768066)
- Testing
- Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Miami
Advanced Refractory Left Ventricular Heart Failure
HeartMate 3™ CE Mark Clinical Investigation Plan
The purpose of this clinical investigation is to evaluate the performance and safety of the HeartMate 3 Left Ventricular Assist System (HM3 LVAS) To support obtaining CE Mark for the HM3 LVAS in Europe, a multi-center clinical…
- Trial name
- HM3 CE Mark (NCT02170363)
- Testing
- Left Ventricular Assist System (LVAS)
- Where
- 10 sites in Australia, Austria and 4 more
- Volunteers
- 50 people
- Sponsor
- Abbott Medical Devices
Stem Cell Transplantation, Ventricular Dysfunction, Left
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
Heart attacks are a leading cause of death in both men and women in the United States. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly…
- Trial name
- PROMETHEUS (NCT00587990)
- Testing
- Lower dose mesenchymal stem cell (MSC) injection, Higher dose MSC injection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Joshua M Hare
Chronic Heart Failure
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
The primary objective of this study is to demonstrate the superiority of ivabradine over placebo in the reduction of cardiovascular mortality or hospitalisation for worsening heart failure in patients with moderate to severe…
- Trial name
- SHIFT (NCT02441218)
- Testing
- Ivabradine
- Where
- 2 sites in France, Sweden
- Volunteers
- 6,505 people
- Sponsor
- Institut de Recherches Internationales Servier
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)
Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI scheduled to undergo cardiac catheterization will be enrolled in the study.
- Trial name
- Trident (NCT02013674)
- Testing
- Allogeneic hMSCs
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua M Hare
Heart Failure, Left Ventricular Dysfunction
Effects of Viagra on Heart Function in Patients With Heart Failure
Sildenafil (Viagra) is known to reduce pulmonary hypertension. Heart failure patients also have pulmonary hypertension and several recent reports have shown that sildenafil leads to an improvement in their exercise capacity.
- Trial name
- NCT00781508
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- MetroHealth Medical Center
Atrioventricular Block, Ventricular Dysfunction
Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization
The primary purpose of the study is to evaluate if patients with a standard indication for permanent ventricular pacing, left ventricular ejection fraction without limit, or any QRS duration will profit from the prevention of…
- Trial name
- NCT00187278
- Testing
- Biventricular Pacing, RV Pacing
- Where
- Germany
- Volunteers
- 1,833 people
- Sponsor
- Abbott Medical Devices
Renal Dialysis, Hemodiafiltration
Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
Introduction: Cardiovascular disease is the leading cause of morbidity and mortality in patients undergoing hemodialysis, largely due to structural cardiac changes associated with left ventricular diastolic dysfunction.
- Conditions
- Renal Dialysis, Hemodiafiltration, Diastolic Dysfunction, Kidney Failure
- Trial name
- EXE-HDF (NCT06584734)
- Testing
- Not exercise, Exercise during hemodiafiltration session
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
Heart Rate Response to Regadenoson and Sudden Cardiac Death
The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
- Trial name
- NCT01842035
- Testing
- regadenoson
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Alabama at Birmingham
Left Ventricular Dysfunction, Right Ventricular Dysfunction
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
This study is to collect data and learn more about the Vscan Ultrasound Imaging System. It is an "observational" study with no additional procedures or intervention prescribed other than using the Vscan along with a routine…
- Conditions
- Left Ventricular Dysfunction, Right Ventricular Dysfunction, Pulmonary Hypertension, Heart Valve Diseases
- Trial name
- NCT01076296
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- GE Healthcare
Left Ventricular Dysfunction
Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)
Prospective, multi-center, single arm, post approval study to be conducted in the United States.
- Trial name
- SMARTMSP (NCT03257436)
- Testing
- CRT-D
- Where
- 54 sites in United States
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- Boston Scientific Corporation
Heart Failure
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed…
- Trial name
- NCT06149104
- Testing
- sacubitril/valsartan
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Ischemic Heart Disease, Left Ventricular Dysfunction
Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all people with CAD are eligible for today's standard treatments.
- Conditions
- Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
- Trial name
- NCT00824005
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- The University of Texas Health Science Center, Houston
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Heart Failure, Asymptomatic Systolic Dysfunction
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
The following are done for screening procedures to determine if patients are eligible for this study: blood count, kidney and liver blood tests. Patients will complete a 6-minute walk test.
- Trial name
- NCT00405639
- Testing
- Nesiritide
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Heart Failure, Cardiomyopathy
Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe.
- Conditions
- Heart Failure, Cardiomyopathy, Ventricular Dysfunction
- Trial name
- NCT02362646
- Testing
- MPC Intramyocardial Injection, Control Solution
- Where
- 19 sites in United States, Canada
- Volunteers
- 159 people
- Sponsor
- Annetine Gelijns
Stress Induced Cardiomyopathy
Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG
Objective: The objective of this pilot study is to characterize the cardiac uptake patterns of I-123 mIBG in stress-induced (Takotsubo's) cardiomyopathy.
- Trial name
- NCT01432626
- Testing
- I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh